Reviewer: Mary Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 10, 2001
Presenter: William G. Woods
Presenter's Affiliation: Emory University, Atlants, GA and Children's Cancer Group, Arcadia, CA
Type of Session: Scientific
Children with AML are frequently treated with more aggressive regimens than adults, and adults under age 40 are often treated with more aggressive regimens than older adults due to increased treatment-related mortality (TRM). Adolescents and young adults (AYAs) can have the acute, proliferative form of AML often seen in children, yet are often treated on adult protocols. It is unknown whether this produces a difference in outcome in this population. This study compares previously untreated AYAs age 16-21 treated on the superior arm of a pediatric protocol with those treated on adult protocols from a single instituion.
Materials and Methods
The authors conclude that patients 16 - 21 years old treated according to the intensive timing arm of CCG 2891 fared better than those treated on the adult regimens of MDACC. Patients from this age group fared as well on adult regimens as those treated on inferior (standard timing) arm of CCG 2891.
This retrospective study suggests that adolescents and young adults aged 16-21 have an improved outcome on more intensive regimens. Adult cancer centers may enroll patients of this age group of intergroup pediatric trials. In the future, more intensive therapy may be directed towards adults under age 45, as well.
Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.